A Phase 2b, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.
The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies.
The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.

Start Date01 Sep 2024

Sponsor / Collaborator

Abivax SA

CTR20232947 / RecruitingPhase 3

一项在中度至重度活动性溃疡性结肠炎受试者中评价ABX464每日一次诱导治疗的有效性和安全性的随机、双盲、安慰剂对照、多中心、3期研究

[Translation] A randomized, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the efficacy and safety of once-daily induction therapy with ABX464 in subjects with moderately to severely active ulcerative colitis

主要目的是比较ABX464与安慰剂在临床缓解方面的有效性。

[Translation]

The primary objective was to compare the effectiveness of ABX464 with placebo in achieving clinical remission.

Start Date12 Mar 2024

Sponsor / Collaborator

Creapharm Clinical Supplies SAS

[+3]

CTRI/2023/05/053075 / RecruitingPhase 3

A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis. – ABTECT Maintenance - ABTECT Maintenance

Start Date29 Sep 2023

Sponsor / Collaborator

Abivax SA

[+1]

100 Clinical Results associated with Obefazimod

100 Translational Medicine associated with Obefazimod

100 Patents (Medical) associated with Obefazimod

Literatures (Medical) associated with Obefazimod

01 Apr 2024·International journal for parasitology. Drugs and drug resistance

Structure-activity relationship and target investigation of 2-aryl quinolines with nematocidal activity

Article

Author: Hofmann, Andreas ; Korhonen, Pasi K ; Wells, Tim N C ; Chang, Bill C H ; Byrne, Joseph J ; Williamson, Nicholas ; Jabbar, Abdul ; Leeming, Michael G ; Wang, Tao ; Young, Neil D ; Keiser, Jennifer ; Zheng, Yuanting ; Nguyen, Nghi ; Taki, Aya C ; Shanley, Harrison T ; Nie, Shuai ; Gasser, Robin B ; Häberli, Cécile ; Ang, Ching-Seng ; Sleebs, Brad E

Within the context of our anthelmintic discovery program, we recently identified and evaluated a quinoline derivative, called ABX464 or obefazimod, as a nematocidal candidate; synthesised a series of analogues which were assessed for activity against the free-living nematode Caenorhabditis elegans; and predicted compound-target relationships by thermal proteome profiling (TPP) and in silico docking. Here, we logically extended this work and critically evaluated the anthelmintic activity of ABX464 analogues on Haemonchus contortus (barber's pole worm) - a highly pathogenic nematode of ruminant livestock. First, we tested a series of 44 analogues on H. contortus (larvae and adults) to investigate the nematocidal pharmacophore of ABX464, and identified one compound with greater potency than the parent compound and showed moderate activity against a select number of other parasitic nematodes (including Ancylostoma, Heligmosomoides and Strongyloides species). Using TPP and in silico modelling studies, we predicted protein HCON_00074590 (a predicted aldo-keto reductase) as a target candidate for ABX464 in H. contortus. Future work aims to optimise this compound as a nematocidal candidate and investigate its pharmacokinetic properties. Overall, this study presents a first step toward the development of a new nematocide.

01 Jan 2024·Bioorganic & medicinal chemistry

Structure activity relationship and target prediction for ABX464 analogues in Caenorhabditis elegans

Article

Author: Hofmann, Andreas ; Wells, Tim N C ; Korhonen, Pasi K ; Byrne, Joseph J ; Williamson, Nicholas ; Jabbar, Abdul ; Gasser, Robin B ; Leeming, Michael G ; Wang, Tao ; Young, Neil D ; Zheng, Yuanting ; Nguyen, Nghi ; Taki, Aya C ; Shanley, Harrison T ; Nie, Shuai ; Sleebs, Brad E ; Ang, Ching-Seng

Global challenges with treatment failures and/or widespread resistance in parasitic worms against commercially available anthelmintics lend impetus to the development of new anthelmintics with novel mechanism(s) of action. The free-living nematode Caenorhabditis elegans is an important model organism used for drug discovery, including the screening and structure-activity investigation of new compounds, and target deconvolution. Previously, we conducted a whole-organism phenotypic screen of the 'Pandemic Response Box' (from Medicines for Malaria Venture, MMV) and identified a hit compound, called ABX464, with activity against C. elegans and a related, parasitic nematode, Haemonchus contortus. Here, we tested a series of 44 synthesized analogues to explore the pharmacophore of activity on C. elegans and revealed five compounds whose potency was similar or greater than that of ABX464, but which were not toxic to human hepatoma (HepG2) cells. Subsequently, we employed thermal proteome profiling (TPP), protein structure prediction and an in silico-docking algorithm to predict ABX464-target candidates. Taken together, the findings from this study contribute significantly to the early-stage drug discovery of a new nematocide based on ABX464. Future work is aimed at validating the ABX464-protein interactions identified here, and at assessing ABX464 and associated analogues against a panel of parasitic nematodes, towards developing a new anthelmintic with a mechanism of action that is distinct from any of the compounds currently-available commercially.

08 Nov 2023·Journal of Crohn's & colitis

Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis

Article

Author: Scherrer, Didier ; d'Agay, Laurence ; Tilg, Herbert ; Gineste, Paul ; Vermeire, Séverine ; Danese, Silvio ; Peyrin-Biroulet, Laurent ; Sands, Bruce E ; Solitano, Virginia ; Ehrlich, Hartmut

Abstract:

Biologic agents and oral small molecules are the mainstays of inflammatory bowel disease [IBD] management. However, an unmet clinical need remains for additional agents with novel mechanism of action which are effective, safe, and disease-modifying; this is due to the substantial proportion of patients who do not respond, lose response, or develop intolerance to currently marketed products. microRNAs [miRNAs] that play a role in the modulation of signal transduction pathways implicated in the development of IBD hold the potential to be used as therapeutic targets. Recently, a novel first-in-class compound, obefazimod, originally conceived as a human immunodeficiency virus [HIV] infection drug, has shown great promise in phase II induction trials for ulcerative colitis [UC] patients. Findings from the maintenance phases of trials showed that long-term obefazimod treatment provides continued improvement in clinical symptoms of disease, with a substantial proportion of patients in clinical remission, and an overall good safety profile. With a novel mechanism of action, obefazimod is an orally available small molecule with anti-inflammatory properties through the specific and selective upregulation of miR-124 expression. The aim of this paper is to critically review the available evidence related to pharmacokinetics and pharmacodynamics, and to discuss the potential clinical implications of this first-in-class oral small molecule.

News (Medical) associated with Obefazimod

20 Jun 2024

·www.fiercepharma.com

AbbVie's rising star Skyrizi nabs key ulcerative colitis FDA approval

With its latest approval, Skyrizi is now approved to treat both of the forms of inflammatory bowel disease. AbbVie’s fast-growing Humira successor Skyrizi is already on a roll with skyrocketing sales. Now, the IL-23 inhibitor is poised to take on an even larger share of Humira’s fading market dominance with a key expansion into ulcerative colitis. On Tuesday, the FDA granted Skyrizi approval to treat adult patents with moderately to severely active ulcerative colitis (UC). The approval adds some 1 million U.S. patients to the drug’s reach and makes Skyrizi the first IL-23 inhibitor cleared to treat both UC and Crohn’s, the two forms of inflammatory bowel disease (IBD). Following a 12-week induction period, patients can dose themselves at home with an on-body injector device “designed with patients in mind," according to AbbVie's press release. The device adheres to the body and delivers the med in about five minutes. Even in a crowded disease area, Skyrizi boasts an edge with prescribers. A Spherix Global Insights poll of 101 gastroenterologists found that doctors are already on board with the med as a UC treatment, with one-third reporting that Skyrizi is a significant advance over existing products. Doctors favor AbbVie’s offering over Johnson & Johnson’s Tremfya and Abivax’s obefazimod, and most are highly familiar with the drug. One gastroenterologist said they prefer Skyrizi because it has “the best efficacy profile among the IL-23 agents.” After its Crohn's approval in 2022, Skyrizi has been a formidable IBD rival to Johnson & Johnson’s blockbuster Stelara. The AbbVie drug has been taking a “significant share” of the J&J med’s sales, AbbVie executives said on an April earnings call. Coupled with its other two approvals in psoriatic arthritis and plaque psoriasis, AbbVie is making strides in its plan to build up Skyrizi—as well as JAK inhibitor Rinvoq—to make up for falling Humira sales. Last year, Skyrizi’s sales reached $7.7 billion, a 50% leap over 2022. The company has long been working on the double threat to buoy its immunology profile as once-king Humira falls to biosimilar competition following its loss of exclusivity in 2023. With the still-rising success of the two drugs, it’s looking like the plan might be coming to fruition even better than AbbVie once hoped. Analysts at GlobalData expect Skyrizi sales to peak in 2030 at $19.7 billion, while Rinvoq should peak at $12.3 billion for a total haul of $32 billion. By the end of the decade, the duo is poised to contribute 42% of AbbVie’s total revenue. “Given their 2030 drug expiries, these drugs are estimated to not only bolster sales for an extended period of time but […] are [also] poised for long-term sales growth, enabling the company to not only financially recover from Humira’s expiry but to also continue its position as a formidable player within the immunology therapy area,” GlobalData pharma analyst Jasper Morley said in the report.

Drug ApprovalBiosimilar

04 Jun 2024

·www.biospace.com

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “General Meeting”), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax (“Board”). The shareholders have adopted all the resolutions proposed by the Board and, in particular, the financial statements for the 2023 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions. The shareholders have also ratified the appointment of Mr. Troy Ignelzi, Dr. June Lee and Ms. Camilla Soenderby as Board members. Details on the vote results will be available on the Company’s website ( ). About Obefazimod Obefazimod, Abivax’s lead investigational drug candidate, is an orally administered small molecule that was demonstrated to potentially enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC have generated positive data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022. Initiation of a Phase 2b clinical trial in Crohn’s disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC is ongoing. About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at . Follow us on LinkedIn and on X, formerly Twitter, @Abivax. Contact Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com +1 847 987 4878 Abivax Communications communications@abivax.com FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business and financial objectives. Words such as “expect,” “potential,” “will” and variations of such words and similar expressions are intended to identify forward-looking statements. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 5, 2024 under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

Phase 2Executive ChangePhase 3

13 Feb 2024

·www.biospace.com

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 21-24, 2024, in Stockholm, Sweden. "We are delighted that all four submitted abstracts have been accepted for presentations at ECCO. We look forward to scientific exchange with the IBD community at ECCO," said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax. "The ECCO Congress provides an excellent platform to present new data and to continue raising awareness of the unique mechanism of action of obefazimod, which available data indicate exerts its anti-inflammatory activity by stabilizing the immune response in patients with ulcerative colitis." Abivax has also sponsored a scientific symposium titled "Expanding the Armamentarium: Emerging MOAs for Treating Ulcerative Colitis" featuring speakers Prof. Bruce E. Sands, M.D., M.S. (United States), and Prof. Raja Atreya, M.D. (Germany), on February 23, 2024, at 7:15-8:15 a.m. CET in room A12. The Symposium will be broadcasted live and is accessible publicly here. No ECCO registration is required to view the broadcast. For more information visit the Abivax booth at the ECCO exhibitor hall (booth #15) or see congress details at the ECCO website. Obefazimod data to be presented: Presentation Title Session Presenter Presentation/ Session Number Session Hall Date and Time (CET) Digital Oral Presentations Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial Session 2: Clinical trials 1 Prof. Séverine Vermeire, M.D., Ph.D. Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC EC24-1273 Digital Oral Presentation (DOP)-12 A7 Feb. 22, 2024 Presentation time: 5:57-6:03 p.m. Session time: 5:45-6:45 p.m. Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose DOP Session 8: Clinical trials 3 Prof. Bruce E. Sands, M.D., M.S. Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY EC24-1275 Digital Oral Presentation (DOP)-71 A12 Feb. 23, 2024 Presentation time: 6:22-6:28 p.m. Session time: 5:40-6:40 p.m. Poster Presentations Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2 Guided Poster Session Didier Scherrer, Ph.D. Chief Scientific Officer, Abivax EC24-1272 Poster Presentation-025 Poster Exhibition Hall A Feb. 23, 2024 Session time: 12:40-1:40 p.m. Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis Guided Poster Session Prof. Parambir S. Dulai, M.D. Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois. EC24-1277 Poster Presentaition-985 Poster Exhibition Hall A Feb. 23, 2024 Session time: 12:40-1:40 p.m. About Obefazimod Obefazimod, Abivax's lead investigational drug candidate, is an oral small molecule that was demonstrated to enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC have generated positive topline data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022. Initiation of a Phase 2b clinical trial in Crohn's disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC is ongoing. About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at . Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX. Contacts: Abivax Communications Regina Jehle regina.jehle@abivax.com +33 06 24 60 69 63 Abivax Investor Relations Patrick Malloy patrick.malloy@abivax.com +1 847 987 4878 FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company's business and financial objectives. Words such as "design," "expect," "forward," "future," "potential," "plan," "project" and variations of such words and similar expressions are intended to identify forward-looking statements. Although Abivax's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d'Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions. SOURCE: ABIVAX View the original press release on accesswire.com

Phase 2Phase 3Clinical Result

100 Deals associated with Obefazimod

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14828

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	Phase 3	AR	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	AU	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	AT	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	BG	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	CA	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	CZ	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	GR	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	HU	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	IN	Abivax SA	10 Oct 2022
Colitis, Ulcerative	Phase 3	NL	Abivax SA	10 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02990325 (CTgov)	Phase 1/2	HIV Infections	36	ABX464 150mg (ABX464 150mg)	jokmhzbjsi(tpbyhvqpex) = obdbkhemsn pmhzhfofcz (cbfrxlhonz, cxzjnlhqpk - yjuxojcdcw) View more	-	31 Mar 2023
				ABX464 50mg (ABX464 50mg for 28 Days)	jokmhzbjsi(tpbyhvqpex) = oxdozozzau pmhzhfofcz (cbfrxlhonz, wqfribiiwn - mpnzcuqzqj) View more
NCT03093259 (CTgov)	Phase 2	Ulcerative colitis, active severe	32	ABX464 (ABX464 Treatment Arm)	ktrjldodrg(fspnvvnnos) = hukabuiywq tisebpimqe (xoivskvbqy, gzhzmtuacb - pqgvewnwrk) View more	-	08 Feb 2023
				Placebo oral capsule (ABX464 Matching Placebo Treatment Arm)	ktrjldodrg(fspnvvnnos) = nrnqmxocwp tisebpimqe (xoivskvbqy, dputwnoqle - nqapnfqhyn) View more
NCT04023396 (UEG2022) Manual	Phase 2	Colitis, Ulcerative	217	Obefazimod	rnjylgopuw(xtoqwugolv) = xqnawllmkq zyvhuipenu (yhbbrxyukm ) View more	Positive	08 Oct 2022
EULAR2022	Phase 2	Rheumatoid Arthritis	60	ABX464 50 mg	aakpdqjhvk(csyejcljxb) = wwckftiivw zzlzytooez (kvgzzdxwim ) View more	-	01 Jun 2022
				ABX464 100 mg	fpavxngyad(dmfloukiql) = pjzsjhdbby dgmkrwhjug (hzztkwgtsm )
NCT03813199 (CTgov)	Phase 2	Rheumatoid Arthritis	60	Matching Placebo+ABX464 50mg+Methotrexate (ABX464 50mg + Methotrexate)	jtlmtwknzs(lfectglize) = awuylytgty vxfudemilc (kepzxduzhg, bwthiwvokc - tgwlzcburz) View more	-	07 Apr 2022
				ABX464 100mg+Methotrexate (ABX464 100mg + Methotrexate)	jtlmtwknzs(lfectglize) = nmxklhlhyw vxfudemilc (kepzxduzhg, vdnvovnkmw - dboxxjxifb) View more
NCT04023396 (Accesswire) Manual	Phase 2	Colitis, Ulcerative	217	ABX464	sildjgrpfo(tiiewszrwt) = zfogegacdg bvssaawhsz (dfpajcdnhk ) View more	Positive	06 Apr 2022
NCT03368118 \| NCT03093259 (Pubmed) Manual	Phase 2	Colitis, Ulcerative	32	ABX464	dhujvaynsj(lfeskhjagg) = ocgzgpklog okycioqqli (aciazekjnz ) View more	Positive	01 Mar 2021
				Placebo	dhujvaynsj(lfeskhjagg) = wwlqlfvsif okycioqqli (aciazekjnz ) View more
EULAR2020	Not Applicable	Inflammation miR-124	-	ABX464	ladvmedgfx(mdajkxslng) = iwlbljdemf fiwyrurrst (qufderarlw ) View more	-	03 Jun 2020
				Placebo	mawsfvtwzg(kcpayfnkea) = bwwccwnurn bukqbvsyry (bgftwwxrtt )
NCT02735863 (Pubmed)	Phase 2	HIV Infections	30	ABX464 50mg	mcaofkvxyv(inhqxcyouh) = bjpkbeyemf qrelxzspgx (sybvxidtuo, 14 - 22) View more	Positive	01 Jan 2019
				ABX464 150mg	mcaofkvxyv(inhqxcyouh) = oswptmokay qrelxzspgx (sybvxidtuo, 10 - 15) View more
NCT02452242 (Pubmed \| Antimicrob Agents Chemother) Manual	Phase 2	HIV Infections First line	66	ABX464	zygengtavy(fsmukrdfgk) = mchaoumapl kvnaudrihe (qjtsqhjwsl )	Positive	27 Jun 2017
				Placebo	zygengtavy(fsmukrdfgk) = tkglvpomno kvnaudrihe (qjtsqhjwsl )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis